Cost-Effectiveness Analysis Of Remdesivir And Favipiravir Therapy For The Treatment Of Covid-19 In Adult Patients At Haji Regional General Hospital, East Java Province
| Main Authors: | Halimbar, Aditya Nugraha, Lorensia, Amelia, Ramadani, Dewi |
|---|---|
| Format: | Article PeerReviewed application/msword application/pdf |
| Bahasa: | eng |
| Terbitan: |
Sean Institute(Science Analytical Institute)
, 2023
|
| Subjects: | |
| Online Access: |
http://repository.ubaya.ac.id/43324/ http://infor.seaninstitute.org/index.php/pendidikan/article/view/1110 |
Daftar Isi:
- Cases of Coronavirus Disease 2019 or COVID-19 from year to year show a tendency to increase spread worldwide, including Indonesia. COVID-19 is an infectious disease caused by a virus so redeliver and Favipiravir antiviral therapy is needed. This study compared the cost-effectiveness analysis of the drugs Ravipiravir and Remdesivir in COVID-19 disease at Haji Hospital Surabaya. This study compares observationally between 2 (two) alternatives using a hospital perspective and data collection carried out retrospectively in the period April 2021 to October 2021. The Cost Effectiveness Analysis method used is the Cost-Effectiveness Ratio (ACER). The results of the data obtained from the ACER cost-effectiveness analysis method in the Favipiravir group are Rp. 2,820,601.63 per day for length of stay and Rp. 6,485,071.79 per day for COVID-19-free time. While in the Remdesivir group Rp. 3,311,510.74 per day for the length of stay and Rp. 8,329,527.98 per day for COVID-19-free time. Meanwhile, the ICER analysis method is Rp. 6,195,280.50 per day for the length of hospitalization and Rp. 34,802,899 per day for COVID-19-free time. This study concludes that Favipiravir is more cost-effective than Remdesivir.